One of the top officials of Cephalosporin bulk drug maker Orchid Chemicals and Pharmaceuticals Ltd has recently confirmed about the company's plans of investing big in therapeutic segments this year.

According to the reports, Orchid Chemicals and Pharmaceuticals Ltd is planning to invest an amount of Rs. 200 crore into formulations in niche therapeutic segments this year.

In context to same, Chairman and Managing Director Mr. K. Raghavendra Rao told the reporters while speaking on the sideline of company's annual general meeting that the proposed investment in the section has been made thinking that it would efficiently support the company's entry into therapeutic segments and at the time when manufacturing process becomes difficult comparatively.

The shareholders have also approved the company's proposal of raising long term funds at recently held general body meeting in which, the shareholders said that raising funds should not exceed Rs. 1,000 crore from domestic or overseas capital markets.

Mr. Rao also confirmed about the ongoing talks between the company and the Tamil Nadu Pollution Control Board (TNPCB) to reopen its active pharmaceutical ingredients (API) plant here, which as earlier ordered to be closed by TNPCB for not complying with the solid waste disposal norms.